Lucero moves to AstraZeneca’s BioVentureHub
Lucero has moved its offices to AstraZeneca’s BioVentureHub in Mölndal, Sweden.
Tinde Höjer joins Lucero team
Tinde Höjer joins the Lucero team to focus on microfluidic development and 3D cell culture handling.
Lucero joins Nanoscale Drug Testing consortium
The consortium aims to develop a “near-patient drug development” strategy that includes using 3D cell models comprised of patient-derived cells. The strategy will reduce clinical failures, enable the development of more effective treatments at a lower cost, and allow the right drug leads to be matched with the right patient subgroup.
Lucero awarded Vinnova Innovative Startups Stage 1 grant
Out of 934 applicants, Lucero was selected by Vinnova, Sweden’s Innovation Agency, as one of the recipients of the Innovative Startups Stage 1 grant. The grant is targeted towards early-stage startups that are based on innovative products and services and that show global growth potential. The money is meant to help startups develop their prototypes and business models, as well as create strategies to protect and commercialize their intellectual assets.
Lucero initiates project with ACTPHAST4.0
With the help of ACTPHAST4.0 partners, VUB B-PHOT Brussels Photonics and Vrije Universiteit Brussel, both world leaders in photonics education, research, and innovation, Lucero aims to optimize our optical setup to maximize its potential to work with 3D cell models, as well as to reduce the size of the system itself.
Lucero receives 50,000 SEK verification grant from Almi Företagspartner Väst
Lucero has been awarded Almi Företagspartner Väst’s verification grant to help fund prototype development that is set to begin this fall.
Lucero joins Chalmers Ventures’ top Accelerator program
Lucero has joined the Gothenburg-based Chalmers Ventures’ Accelerator program. The Accelerator has been supporting great founders and startups since 1999 through mentoring, investment, and access to Chalmers Ventures’ broad network of professionals.
Lucero accepted to Cohort 1 – HealthTech, BioTech, & MedTech, of X-Europe program
Lucero will participate in the X-Europe program this fall to further develop our product-market fit and find future corporate collaboration partners.
Lucero awarded €150,000 ERC Proof of Concept grant to begin prototype development
We are very honored and happy to share that from the hands of our great advisor Dr. Giovanni Volpe, Lucero was selected as one of only three projects from Sweden to receive the Proof of Concept Grant (PoC) from the European Research Council. This grant aims to explore the commercial and societal potential of the very best and most innovative research from the European Union.